Topotecan/Cisplatin For Late-Stage Cervical Cancer

Cervical Cancer

The FDA has approved a combination of the antineoplastic drug topotecan HCl (Hycamtin, GlaxoSmithKline) and the alkylating agent cisplatin (Platinol, Bristol-Myers Squibb) as the first pharmaceutical treatment for women with late-stage cancer of the cervix for which surgery or radiation therapy is unlikely to be effective.

Hycamtin was approved in 1996 for treating ovarian cancer and in 1998 for treating small-cell lung cancer. The combination is specifically indicated for women with stage IVB (incurable), recurrent, or persistent cervical cancer.